IBI318
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IBI318, covering 2025-03-05 to 2025-03-05. Get the full timeline:
Most recent: Clinical Trial Update: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. [Phase 2]